Science Explorer Back to mapMap
Discussion
Company · Karmiel · Israel

Protalix BioTherapeutics (Israel)

protalix.comROR OpenAlex
Research works
41
▼ 40% vs 2018-21
Citations
1.6k
39.9 per fractional work
Top-10% rate
7.2%
all institutions 10.0%
Open access
39%
world 40%
International
42%
world 18%
Protalix BioTherapeutics (Israel)

Not ranked overall: Protalix BioTherapeutics (Israel) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Protalix BioTherapeutics (Israel) work in?

In all years, 45% of research at Protalix BioTherapeutics (Israel) is in Life Sciences, 35% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (37%), Medicine (34%), Chemistry (8%). It does 2.3× the world's share of Life Sciences.

Life Sciences: 18 fractional works · 44.9% of its workBiochemistry, Genetics and Molecular Biology: 15 fractional works · 36.7% of its workMolecular Biology: 10 fractional works · 25.0% of its workBiotechnology: 4 fractional works · 8.7% of its workCell Biology: 0 fractional works · 1.0% of its workGenetics: 0 fractional works · 0.9% of its workClinical Biochemistry: 0 fractional works · 0.4% of its workEndocrinology: 0 fractional works · 0.4% of its workBiophysics: 0 fractional works · 0.2% of its workImmunology and Microbiology: 2 fractional works · 5.7% of its workImmunology: 2 fractional works · 5.1% of its workMicrobiology: 0 fractional works · 0.4% of its workVirology: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 1 fractional works · 1.5% of its workAnimal Science and Zoology: 0 fractional works · 0.7% of its workPlant Science: 0 fractional works · 0.5% of its workAquatic Science: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.0% of its workNeuroscience: 0 fractional works · 1.0% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.6% of its workCognitive Neuroscience: 0 fractional works · 0.4% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.0% of its workHealth Sciences: 14 fractional works · 34.6% of its workMedicine: 14 fractional works · 33.8% of its workPhysiology: 7 fractional works · 15.8% of its workEpidemiology: 3 fractional works · 7.2% of its workHematology: 1 fractional works · 2.6% of its workHepatology: 1 fractional works · 2.0% of its workOncology: 1 fractional works · 1.8% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 1.4% of its workRheumatology: 0 fractional works · 0.5% of its workPathology and Forensic Medicine: 0 fractional works · 0.4% of its workImmunology and Allergy: 0 fractional works · 0.4% of its workNephrology: 0 fractional works · 0.4% of its workComplementary and alternative medicine: 0 fractional works · 0.3% of its workInfectious Diseases: 0 fractional works · 0.3% of its workRehabilitation: 0 fractional works · 0.3% of its workSurgery: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workNursing: 0 fractional works · 0.8% of its workNutrition and Dietetics: 0 fractional works · 0.8% of its workPhysical Sciences: 7 fractional works · 17.8% of its workChemistry: 3 fractional works · 8.3% of its workOrganic Chemistry: 2 fractional works · 5.5% of its workPhysical and Theoretical Chemistry: 1 fractional works · 2.0% of its workSpectroscopy: 0 fractional works · 0.8% of its workEngineering: 3 fractional works · 6.3% of its workBiomedical Engineering: 2 fractional works · 6.1% of its workAerospace Engineering: 0 fractional works · 0.2% of its workChemical Engineering: 0 fractional works · 0.8% of its workFluid Flow and Transfer Processes: 0 fractional works · 0.8% of its workComputer Science: 0 fractional works · 0.8% of its workComputational Theory and Mathematics: 0 fractional works · 0.8% of its workPhysics and Astronomy: 0 fractional works · 0.8% of its workAtomic and Molecular Physics, and Optics: 0 fractional works · 0.8% of its workEnvironmental Science: 0 fractional works · 0.4% of its workEcology: 0 fractional works · 0.4% of its workEnergy: 0 fractional works · 0.3% of its workRenewable Energy, Sustainability and the Environment: 0 fractional works · 0.3% of its workMaterials Science: 0 fractional works · 0.1% of its workSocial Sciences: 1 fractional works · 2.7% of its workSocial Sciences: 1 fractional works · 1.3% of its workSociology and Political Science: 1 fractional works · 1.3% of its workArts and Humanities: 0 fractional works · 1.2% of its workHistory and Philosophy of Science: 0 fractional works · 1.2% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.2% of its workEconomics and Econometrics: 0 fractional works · 0.2% of its workALL ITS WORKProtalixBioTherapeutics…41fractional works, all years
Life Sciences45%Physical Sciences18%Health Sciences35%Social Sciences3%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 18 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology1536.7%
    2. Immunology and Microbiology25.7%
    3. Agricultural and Biological Sciences11.5%
    4. Neuroscience01.0%
    5. Pharmacology, Toxicology and Pharmaceutics00.0%
    1. Medicine1433.8%
    2. Nursing00.8%
    1. Chemistry38.3%
    2. Engineering36.3%
    3. Chemical Engineering00.8%
    4. Computer Science00.8%
    5. Physics and Astronomy00.8%
    6. Environmental Science00.4%
    7. Energy00.3%
    8. Materials Science00.1%
    1. Social Sciences11.3%
    2. Arts and Humanities01.2%
    3. Economics, Econometrics and Finance00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.29× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 4.70× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 11.87× its world share, 1 worksImmunology and Micro…Chemistry: 6.13× its world share, 0 worksChemistryComputer Science: 0.79× its world share, 0 worksComputer ScienceMaterials Science: 0.14× its world share, 0 worksMaterials ScienceMedicine: 1.86× its world share, 2 worksMedicineSocial Sciences: 0.76× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 11.9×. Every wedge is a field page.

All 8 fields, with their numbers
  1. Immunology and Microbiology11.87×1 works
  2. Chemistry6.13×0 works
  3. Biochemistry, Genetics and Molecular Biology4.70×1 works
  4. Medicine1.86×2 works
  5. Computer Science0.79×0 works
  6. Social Sciences0.76×0 works
  7. Agricultural and Biological Sciences0.29×0 works
  8. Materials Science0.14×0 works

Who are the top researchers at Protalix BioTherapeutics (Israel)?

Ranked on the quality score, Yoseph Shaaltiel, Einat Brill‐Almon and Arie Zauberman lead among researchers whose main affiliation is Protalix BioTherapeutics (Israel).

  1. 1 Yoseph Shaaltiel Israel · #470,516 worldwide 2.5k citations · 49 works
  2. 2 Einat Brill‐Almon Israel · #1,663,099 worldwide 1.4k citations · 35 works
  3. 3 Arie Zauberman Israel · #1,684,816 worldwide 996 citations · 15 works
  4. 4 Einat Brill Almon Israel · #2,906,733 worldwide 676 citations · 39 works
  5. 5 Sari Alon Israel · #3,484,026 worldwide 483 citations · 49 works
  6. 6 Raul Chertkoff Israel · #4,741,768 worldwide 1.3k citations · 103 works
All ranked researchers at Protalix BioTherapeutics (Israel)

What are the most cited papers from Protalix BioTherapeutics (Israel)?

The most cited paper from Protalix BioTherapeutics (Israel) is "Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system" (Yoseph Shaaltiel, Daniel Bartfeld, Sharon Hashmueli et al., 2007), with 433 citations. Next come "The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): A novel, pleiotropic member of the C-X-C chemokine superfamily" (357) and "Small interfering RNA Inhibits Hepatitis B virus replication in mice" (308).

Most cited papers
#PaperReleasedCitations
1 Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system Yoseph Shaaltiel, Daniel Bartfeld, Sharon Hashmueli et al. · Plant Biotechnology Journal Open access 24 May 2007 433
2 The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): A novel, pleiotropic member of the C-X-C chemokine superfamily Lewis F. Neville, Guenther Mathiak, Omar Bagasra · Cytokine & Growth Factor Reviews Review Sep 1997 357
3 Small interfering RNA Inhibits Hepatitis B virus replication in mice Hilla Giladi, Mali Ketzinel‐Gilad, Ludmila Rivkin et al. · Molecular Therapy Open access Nov 2003 308
4 Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease Ari Zimran et al. · Blood Open access 7 Sep 2011 210
5 Large‐scale production of pharmaceutical proteins in plant cell culture—the protalix experience Yoram Tekoah, Avidor Shulman, Tali A. Kizhner et al. · Plant Biotechnology Journal Open access 23 Jun 2015 193
All 59 most cited papers, with filters and sorting

Which keywords describe research at Protalix BioTherapeutics (Israel)?

By fractional works in all years, weighted toward what it does more of than the world: Enzyme Replacement Therapy, Lysosomal Storage Disorders, Biopharmaceuticals, Plant Molecular Farming, Recombinant Proteins, Immune Response, Glycosylation and Glycosidase Inhibitors.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 35 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 35 words, with their numbers
  1. Enzyme Replacement Therapy6▲ 586×1 topic
  2. Lysosomal Storage Disorders6▲ 811×1 topic
  3. Epidemiology3▲ 1.98×11 topics
  4. Biopharmaceuticals3▲ 108×2 topics
  5. Plant Molecular Farming3▲ 299×1 topic
  6. Recombinant Proteins3▲ 137×1 topic
  7. Immune Response3▲ 11×8 topics
  8. Cancer3▲ 4.6×8 topics
  9. Glycosylation2▲ 28×3 topics
  10. Inflammation2▲ 2.3×11 topics
  11. Glycosidase Inhibitors2▲ 108×1 topic
  12. Oligosaccharide Synthesis2▲ 108×1 topic
  13. Gene Expression2▲ 8.5×2 topics
  14. Agrobacterium-Mediated Transformation2▲ 85×1 topic
  15. Plant Secondary Metabolites2▲ 66×1 topic
  16. Antiviral Therapy2▲ 29×2 topics
  17. Liver Disease2▲ 32×2 topics
  18. Lab-on-a-Chip2▲ 29×2 topics
  19. Chemotherapy2▲ 5.0×2 topics
  20. Drug Resistance2▲ 11×2 topics
  21. Chagas Disease1▲ 129×1 topic
  22. Trypanosoma cruzi1▲ 129×1 topic
  23. Cancer Therapy1▲ 5.1×6 topics
  24. Glycans1▲ 38×1 topic
  25. Immune System1▲ 9.5×1 topic
  26. Lipid Rafts1▲ 46×1 topic
  27. Membrane Lipids1▲ 54×1 topic
  28. Biomedical Research1▲ 37×1 topic
  29. Genome Engineering1▲ 49×1 topic
  30. Hepatocellular Carcinoma1▲ 14×2 topics
  31. Poly(dimethylsiloxane)1▲ 58×1 topic
  32. RNA-Guided1▲ 49×1 topic
  33. Global Burden1▲ 4.8×2 topics
  34. Chronic Hepatitis B1▲ 46×1 topic
  35. Hepatitis B Virus1▲ 46×1 topic

Which research topics does Protalix BioTherapeutics (Israel) publish most on?

By volume in 2022-now: Lysosomal Storage Disorders Research, Advanced Proteomics Techniques and Applications, PARP inhibition in cancer therapy and Chromatin Remodeling and Cancer.

Lysosomal Storage Disord…1Lysosomal Storage Disorders Research: 1 fractional worksAdvanced Proteomics Tech…0Advanced Proteomics Techniques and Applications: 0 fractional worksPARP inhibition in cancer therapy: 0 fractional worksChromatin Remodeling and Cancer: 0 fractional worksProtein Degradation and …0Protein Degradation and Inhibitors: 0 fractional worksMelanoma and MAPK Pathways: 0 fractional worksComputational Drug Discovery Methods: 0 fractional worksNeutrophil, Myeloperoxid…0Neutrophil, Myeloperoxidase and Oxidative Mechanisms: 0 fractional worksEuropean Cultural and National Identity: 0 fractional worksLiterature, Language, and Rhetoric Studies: 0 fractional works
PhysiologySpectroscopyOncologyMolecular Biology3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Lysosomal Storage Disorders Research Physiology 1 works
  2. 2 Advanced Proteomics Techniques and Applications Spectroscopy 0 works
  3. 3 PARP inhibition in cancer therapy Oncology 0 works
  4. 4 Chromatin Remodeling and Cancer Molecular Biology 0 works
  5. 5 Protein Degradation and Inhibitors Molecular Biology 0 works
  6. 6 Melanoma and MAPK Pathways Molecular Biology 0 works
  7. 7 Computational Drug Discovery Methods Computational Theory and Mathematics 0 works
  8. 8 Neutrophil, Myeloperoxidase and Oxidative Mechanisms Immunology 0 works
  9. 9 European Cultural and National Identity Sociology and Political Science 0 works
  10. 10 Literature, Language, and Rhetoric Studies Sociology and Political Science 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available38.9%not open61.1%

World: 40% of research is openly available.

with international co-authors42.5%domestic only57.5%

World: 18% is written across borders.

How has Protalix BioTherapeutics (Israel)'s research output changed?

Output in 2022-2025 was 40% lower than in 2018-2021.

still counting200020052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Protalix BioTherapeutics (Israel) as a percentage of every work published that year, 0.000017% in 2024.

still counting0.00010%0.00020%Protalix BioTherapeutics (Israel)0.000039% in 2025200020102020

Fractional works of Protalix BioTherapeutics (Israel) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Karmiel

All research institutions in Karmiel

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Protalix BioTherapeutics (Israel). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.